(Q36276485)

13 August 2017

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer (English)

1 reference

13 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

1 reference

1 reference

S Modi

9

0 references

Larry Norton

object named as

L Norton

13

0 references

author name string

M N Fornier

1

1 reference

13 August 2017

P G Morris

2

1 reference

13 August 2017

A Abbruzzi

3

1 reference

13 August 2017

G D'Andrea

4

1 reference

13 August 2017

T Gilewski

5

1 reference

13 August 2017

J Bromberg

6

1 reference

13 August 2017

C Dang

7

1 reference

13 August 2017

M Dickler

8

1 reference

13 August 2017

A D Seidman

10

1 reference

13 August 2017

N Sklarin

11

1 reference

13 August 2017

J Chang

12

1 reference

13 August 2017

C A Hudis

14

1 reference

13 August 2017

15 March 2011

1 reference

13 August 2017

1 reference

13 August 2017

22

1 reference

13 August 2017

12

1 reference

13 August 2017

2575-2581

1 reference

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

30 September 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Overriding imatinib resistance with a novel ABL kinase inhibitor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Src kinase activity is essential for osteoclast function

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Therapeutic options for metastatic breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4643618

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR018

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR018

C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21406471

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDR018

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

21406471

1 reference